CL2008002853A1 - Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02) - Google Patents

Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02)

Info

Publication number
CL2008002853A1
CL2008002853A1 CL2008002853A CL2008002853A CL2008002853A1 CL 2008002853 A1 CL2008002853 A1 CL 2008002853A1 CL 2008002853 A CL2008002853 A CL 2008002853A CL 2008002853 A CL2008002853 A CL 2008002853A CL 2008002853 A1 CL2008002853 A1 CL 2008002853A1
Authority
CL
Chile
Prior art keywords
mif
angiogenesis
quinoline
arthritis
inflammation
Prior art date
Application number
CL2008002853A
Other languages
Spanish (es)
Inventor
Kumar K C Sunil
C A Gaeta Federico
Baird Andrew
Anchin Jerry
Ying Wenbin
Florkiewicz Robert
Sircar Jagadish
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51399105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of CL2008002853A1 publication Critical patent/CL2008002853A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de piraziin-quinolina sustituida, inhibidores de la migración de macrófagos (MIF); procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de inflamación, shock séptico, artritis, cáncer, trastornos autoinmunes e inhibición de angiogénesis.Compounds derived from substituted piraziin-quinoline, macrophage migration (MIF) inhibitors; preparation procedure; pharmaceutical composition; and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis.

CL2008002853A 2002-05-24 2008-09-25 Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02) CL2008002853A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29364202P 2002-05-24 2002-05-24

Publications (1)

Publication Number Publication Date
CL2008002853A1 true CL2008002853A1 (en) 2008-12-26

Family

ID=51399105

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002853A CL2008002853A1 (en) 2002-05-24 2008-09-25 Compounds derived from substituted pyraziin quinoline, macrophage migration inhibitors (mif); and its use in the treatment of inflammation, septic shock, arthritis, cancer, autoimmune disorders and inhibition of angiogenesis (divisional of application 1088-02)

Country Status (1)

Country Link
CL (1) CL2008002853A1 (en)

Similar Documents

Publication Publication Date Title
WO2004020599A3 (en) Hedgehog antagonists, methods and uses related thereto
BRPI0418112A (en) heterocyclic bicyclic p-38 kinase inhibitors
CL2003002353A1 (en) COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
DE69732868D1 (en) Remedy for itching
CY1106357T1 (en) ADAMANTANIUM DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY, IMMUNE AND CARDIOVASCULAR DISEASES
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
ATE267168T1 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
DE60142921D1 (en) AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS
BR9910864A (en) Anti-inflammatory compounds for inhibiting cell adhesion
DE60118003D1 (en) UREA DERIVATIVES AND ITS USE
WO2005023761A3 (en) Cytokine inhibitors
BRPI0410905A (en) p-38 inhibitors
EP1007556A4 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
DE60324544D1 (en) MUSCARIN ANTAGONISTS
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
BRPI0515721A (en) use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination
EA200100732A1 (en) ANTI-INFLAMMATORY AND IMMUNOSUPRESSOR COMPOUNDS INHIBITING CELLULAR ADHESION
DE69919179D1 (en) SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONE AND THEIR ANALOGS, AND THEIR USE
MXPA04006555A (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists.
EA200200545A1 (en) ONCOLYTIC COMBINATIONS FOR CANCER TREATMENT
MEP16208A (en) A combination comprising combretastatin and anticancer agents
SI1492773T1 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
MXPA05003718A (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof.
AR024907A1 (en) USE OF INHIBITORS OF THE PRODUCTION AND / OR ACTION OF IL-18 AND PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH INHIBITORS FOR THE TUMORS DEMETASTASIS TREATMENT.